Literature DB >> 1618180

Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide.

T Warner1, P N Patsalos, M Prevett, A A Elyas, J S Duncan.   

Abstract

We report an interaction between lamotrigine (LTG), a new antiepileptic drug (AED), and carbamazepine (CBZ) and its primary metabolite CBZ-10,11-epoxide (CBZ-E) in 9 consecutive patients (5 male, 4 female, aged 19-31 years). After introduction of LTG (median daily dose 200 mg, range 100-300 mg) the mean serum CBZ-E concentration increased by 45% (P less than 0.01) and the CBZ-E/CBZ ratio increased by 19% (P less than 0.02). In 4 patients these changes were associated with clinical toxicity (dizziness, nausea, diplopia). The possibility of an increase in serum CBZ-E concentrations needs to be considered if toxicity symptoms develop when LTG is added to CBZ therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618180     DOI: 10.1016/0920-1211(92)90049-y

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  23 in total

Review 1.  The new antiepileptic drugs.

Authors:  R E Appleton
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

2.  Discordant carbamazepine values between two immunoassays: carbamazepine values determined by ADVIA Centaur correlate better with those determined by LC-MS/MS than PETINIA assay.

Authors:  Gwendolyn A McMillin; Joetta M Juenke; Myrtle J Johnson; Amitava Dasgupta
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

Review 3.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 4.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 5.  Pharmacokinetic interactions of the new antiepileptic drugs.

Authors:  B Rambeck; U Specht; P Wolf
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

6.  Effect of lamotrigine on the pharmacokinetics of carbamazepine and its active metabolite in dogs.

Authors:  K M Matar; P J Nicholls; S A Bawazir; K I Al-Khamis; M I Al-Hassan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

Review 7.  Newer anticonvulsants: comparative review of drug interactions and adverse effects.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 8.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 9.  Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.

Authors:  K L Goa; S R Ross; P Chrisp
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

10.  Vigabatrin and lamotrigine in refractory epilepsy.

Authors:  I Stolarek; J Blacklaw; G Forrest; M J Brodie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.